A Two-Tier Alzheimer’s Dementia System Is Emerging in Ontario
Ontario is quietly developing a two-tier system for the diagnosis and management of Alzheimer’s dementia.

Today, two patients with the same early symptoms of memory loss can receive completely different levels of care depending on whether they have private financial resources or must rely entirely on OHIP.

 

 

 

 

 

The Private Diagnostic and Treatment Pathway Already Exists
Patients with disposable income or private insurance can now access a growing range of modern Alzheimer’s biomarker tests through private laboratories such as Dynacare and LifeLabs.

These include:

Plasma P-tau217 blood testing
ApoE4 genetic testing
Amyloid Beta 42:40 ratio testing
Private PET imaging
One of the most important of these newer tests is the plasma phosphorylated tau blood test, commonly referred to as the P-tau217 blood test.

This test costs approximately $325 CAD privately.

Meanwhile, amyloid PET imaging can cost approximately $4,000 CAD privately.

Patients with sufficient financial means may also pursue newer monoclonal antibody therapies approved by Health Canada, which can cost over $30,000 per year and often require biomarker confirmation before treatment eligibility.

In practice, a private Alzheimer’s diagnostic ecosystem already exists in Ontario for those who can afford it.

 

 

 

 

 The Public OHIP Pathway Remains Largely Stuck in the Past
By contrast, patients dependent entirely upon OHIP are often limited to older diagnostic pathways.

For decades, Alzheimer’s dementia was primarily considered a diagnosis of exclusion. Physicians ruled out other causes of memory loss such as:

Stroke
Brain tumors
Thyroid disease
Vitamin deficiencies
Depression
Medication side effects
Other neurological conditions
Patients commonly undergo cognitive testing along with CT or MRI scans, which are mainly used to exclude alternative diagnoses rather than directly confirm Alzheimer’s dementia pathology itself.

Ironically, this older approach may already be more expensive in many situations.

CT and MRI imaging can cost approximately $1,000 CAD, yet these investigations are frequently ordered primarily to rule out other conditions even when no focal neurological symptoms are present.

Meanwhile, highly specific blood biomarkers for Alzheimer’s disease now exist.

This creates a very real two-tier system:

Wealthier patients can access modern biological diagnosis privately.
OHIP-dependent patients remain restricted to older exclusion-based assessment models.

 

 

 

 

Alzheimer’s Dementia Diagnosis Has Changed Worldwide
The world has moved toward biologically based Alzheimer’s diagnosis.

In 2024, the Alzheimer's Association published revised diagnostic criteria recognizing that Alzheimer’s disease can now be identified biologically using biomarkers, including blood-based biomarkers such as plasma P-tau217.

Reference:
2024 Alzheimer’s Association revised diagnostic criteria

https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.13859

Summary:
Alzheimer’s Association summary of revised criteria

https://www.alz.org/news/2024/revised-alzheimers-diagnostic-staging-criteria

This represents a major shift in dementia medicine.

Alzheimer’s disease is increasingly being approached like many other diseases in modern medicine where biological testing assists diagnosis early, often before severe irreversible decline occurs.

Research over recent years has demonstrated that plasma P-tau217 correlates strongly with Alzheimer’s pathology identified on PET scans and cerebrospinal fluid testing.

Historically, confirming Alzheimer’s pathology required:

Lumbar puncture
Amyloid PET imaging
Tau PET imaging
These tests are invasive, expensive, or difficult to access.

Blood biomarkers are changing this dramatically.

A simple blood test can now provide highly sensitive and specific information regarding the likelihood of Alzheimer’s pathology.

Importantly, these biomarkers may become abnormal years before severe dementia develops.

 

 

 

 

Early Diagnosis Matters
Earlier diagnosis allows patients and families to:

Plan finances and future care
Address driving and safety concerns
Complete legal planning while capacity remains intact
Access support services sooner
Participate in research studies
Consider lifestyle interventions
Make informed decisions regarding potential therapies
This is becoming increasingly important as disease-modifying Alzheimer’s treatments begin to emerge.

 

 

 

 

What This Petition Is Asking For
This petition is not asking OHIP to fund expensive PET scans or costly Alzheimer’s medications.

 

It is asking for one specific, limited, and comparatively affordable step:

Make the P-tau217 blood test available under OHIP for patients being assessed for suspected early Alzheimer’s dementia or mild cognitive impairment.
The test could potentially be funded once per lifetime, similar to how Lipoprotein(a) testing is approached.

Compared with expensive imaging pathways, blood testing is:

Faster
Less invasive
Easier to scale
Associated with minimal wait times
Earlier biomarker-based assessment may also improve triage and reduce unnecessary imaging investigations.

At approximately $325 CAD, this represents a modest but meaningful modernization of dementia care in Ontario.

Patients should not need private wealth simply to access modern Alzheimer’s diagnostic medicine.

 

This is why I believe P-tau217 Blood Test for Early Alzheimer’s Dementia Detection should be Covered Under OHIP($325)

 

Dr. S. Rawat is a Family Physician based in Toronto and founder of www.healthgroupcoaching.com where he provides a OHIP-covered group coaching program focused on weight loss and reversal of metabolic disease

 

 

 

 

https://healthgroupcoaching.com/f/top-5-evidence-based-dietary-strategies-for-brain-health​

 

https://healthgroupcoaching.com/f/top-5-lifestyle-and-dietary-interventions-to-prevent-a-stroke​

 

https://healthgroupcoaching.com/f/can-arterial-plaque-really-regress-with-diet​

 

https://healthgroupcoaching.com/f/top-5-most-impactful-strategies-to-prevent-osteoporosis

 

 

Scientific evidence supporting P-tau217
Study 1
Title: Revised criteria for diagnosis and staging of Alzheimer’s disease
Authors: Clifford R. Jack Jr. et al.
Year: 2024
Journal: Alzheimer’s & Dementia
Design: Expert workgroup diagnostic criteria revision

Key findings:
Plasma p-tau217 and other biomarkers were incorporated into biological diagnosis and staging frameworks for Alzheimer’s disease.

Conclusion:
Blood biomarkers are now considered central to modern Alzheimer’s diagnostic frameworks.

Original:
https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.13859

 
Study 2
Title: A Blood Test for Alzheimer’s? Markers for Tau Take Us a Step Closer
Year: 2020
Conference: Alzheimer’s Association International Conference
Design: Observational biomarker studies

Key findings:
Plasma p-tau217 shows high specificity for Alzheimer’s pathology and may detect disease-related changes years before dementia becomes severe.

Original:
https://aaic.alz.org/releases_2020/blood-biomarkers-tau.asp

 
Study 3
Title: Alzheimer’s Association Clinical Practice Guideline for Blood-Based Biomarkers
Year: 2025
Organization: Alzheimer’s Association
Design: Evidence review (49 studies, 31 biomarkers)

Key findings:
Selected blood biomarkers show sensitivity above 90% with strong specificity and may be used in clinical diagnostic pathways.

Original:
https://aaic.alz.org/releases-2025/clinical-practice-guideline-blood-based-biomarkers.asp